Scientific Publications: 2005

Pre–Clinical Studies

  1. Louder MK, Sambor A, Chertova E, Hunte T, Barrett S, Ojong F, Sanders-Buell E, Zolla-Pazner S, McCutchan FE, Roser JD, Gabuzda D, Lifson JD, Mascola JR. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology. 2005 Sep 1;339(2):226-38.
  2. Currier JR, Harris ME, Cox JH, McCutchan FE, Birx DL, Maayan S, Ferrari G. Immunodominance and cross-reactivity of B5703-restricted CD8 T lymphocytes from HIV type 1 subtype C-infected Ethiopians. AIDS Res Hum Retroviruses. 2005 Mar;21(3):239-45.
  3. Rutebemberwa A, Currier JR, Jagodzinski L, McCutchan F, Birx D, Marovich M, Cox JH. HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T cell responses compared with consensus subtypes B and M group 15-mer peptides. AIDS. 2005 Jul 22;19(11):1165-72.
  4. Brown BK, Darden JM, Tovanabutra S, Oblander T, Frost J, Sanders-Buell E, de Souza MS, Birx DL, McCutchan FE, Polonis VR. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J Virol. 2005 May;79(10):6089-101.
  5. Chen X, Rock MT, Hammonds J, Tartaglia J, Shintani A, Currier J, Slike B, Crowe JE Jr, Marovich M, Spearman P. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses. J Virol. 2005 May;79(9):5537-47.
  6. Maecker HT, Rinfret A, D'Souza P, Darden J, Roig E, Landry C, Hayes P, Birungi J, Anzala O, Garcia M, Harari A, Frank I, Baydo R, Baker M, Holbrook J, Ottinger J, Lamoreaux L, Epling CL, Sinclair E, Suni MA, Punt K, Calarota S, El-Bahi S, Alter G, Maila H, Kuta E, Cox J, Gray C, Altfeld M, Nougarede N, Boyer J, Tussey L, Tobery T, Bredt B, Roederer M, Koup R, Maino VC, Weinhold K, Pantaleo G, Gilmour J, Horton H, Sekaly RP. Standardization of cytokine flow cytometry assays. BMC Immunol. 2005 Jun 24;6:13.
  7. Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, D'souza MP; Elispot Collaborative Study Group. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses. 2005 Jan;21(1):68-81.
  8. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005 Aug;79(16):10108-25.
  9. Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L, Petropoulos CJ, Polonis VR, Sarzotti M, Montefiori DC. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol. 2005 Aug; 79(16):10103-7.
  10. Ockenhouse CF, Bernstein WB, Wang Z, Vahey MT. Functional genomic relationships in HIV-1 disease revealed by gene-expression profiling of primary human peripheral blood mononuclear cells. J Infect Dis. 2005 Jun 15;191(12):2064-74.
  11. McCutchan FE, Hoelscher M, Tovanabutra S, Piyasirisilp S, Sanders-Buell E, Ramos G, Jagodzinski L, Polonis V, Maboko L, Mmbando D, Hoffmann O, Riedner G,von Sonnenburg F, Robb M, Birx DL. In-depth analysis of a heterosexually acquired human immunodeficiency virus type 1 superinfection: evolution, temporal fluctuation, and intercompartment dynamics from the seronegative window period through 30 months postinfection. J Virol. 2005 Sep;79(18):11693-704.
  12. Arroyo MA, Hoelscher M, Sateren W, Samky E, Maboko L, Hoffmann O, Kijak G, Robb M, Birx DL, McCutchan FE. HIV-1 diversity and prevalence differ between urban and rural areas in the Mbeya region of Tanzania. AIDS. 2005 Sep 23;19(14):1517-1524.
  13. Gerhardt M, Mloka D, Tovanabutra S, Sanders-Buell E, Hoffmann O, Maboko L, Mmbando D, Birx DL, McCutchan FE, Hoelscher M. In-depth, longitudinal analysis of viral quasispecies from an individual triply infected with late-stage human immunodeficiency virus type 1, using a multiple PCR primer approach. J Virol. 2005 Jul;79(13):8249-61.
  14. Wolfe ND, Heneine W, Carr JK, Garcia AD, Shanmugam V, Tamoufe U, Torimiro JN, Prosser AT, Lebreton M, Mpoudi-Ngole E, McCutchan FE, Birx DL, Folks TM, Burke DS, Switzer WM. Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. Proc Natl Acad Sci U S A. 2005 May 31;102(22):7994-9.
  15. Peachman KK, Rao M, Alving CR, Palmer DR, Sun W, Rothwell SW. Human dendritic cells and macrophages exhibit different intracellular processing pathways for soluble and liposome-encapsulated antigens. Immunobiology. 2005;210(5):321-33.
  16. Janetzki S, Cox JH, Oden N, Ferrari G. Standardization and validation issues of the ELISPOT assay. Methods Mol Biol. 2005;302:51-86.
  17. Wang Z, Lewis MG, Nau ME, Arnold A, Vahey MT. Identification and utilization of inter-species conserved (ISC) probesets on Affymetrix human GeneChip platforms for the optimization of the assessment of expression patterns in non-human primate (NHP) samples. BMC Bioinformatics. 2004 Oct 26;5:165.
  18. Petrovics G, Liu A, Shaheduzzaman S, Furasato B, Sun C, Chen Y, Nau M, Ravindranath L, Chen Y, Dobi A, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Moul JW, Srivastava S. Frequent over expression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005 May 26;24(23):3847-52.
  19. Schaecher K, Kumar S, Yadava A, Vahey M, Ockenhouse CF. Genome-wide expression profiling in malaria infection reveals transcriptional changes associated with lethal and nonlethal outcomes. Infect Immun. 2005 Sep;73(9):6091-100.
  20. Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Brown AE, Gurunathan S, Tartaglia J, Heyward WL, McNeil JG, Birx DL, de Souza MS; Thai AIDS Vaccine Evaluation Group, Thailand. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine. 2005 Mar 31;23(19):2522-9.
  21. Lu XC, Williams AJ, Yao C, Berti R, Hartings JA, Whipple R, Vahey MT, Polavarapu RG, Woller KL, Tortella FC, Dave JR. Microarray analysis of acute and delayed gene expression profile in rats after focal ischemic brain injury and reperfusion. J Neurosci Res. 2004 Sep 15;77(6):843-57.
  22. Richards RL, Rao M, Vancott TC, Matyas GR, Birx DL, Alving CR. Liposome-stabilized oil-in-water emulsions as adjuvants: increased emulsion stability promotes induction of cytotoxic T lymphocytes against an HIV envelope antigen. Immunol Cell Biol. 2004 Oct; 82(5):531-8.
  23. Rao M, Matyas GR, Vancott TC, Birx DL, Alving CR. Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein. Immunol Cell Biol. 2004 Oct;82(5):523-30.
  24. Alving, C.R., and Matyas, G.R. Design and selection of vaccine adjuvants: Principles and practice. "Birkhäuser Advances in Infectious Diseases" The grand challenge for the future: Vaccines for poverty-related diseases from bench to field. Editors: Stefan H.E. Kaufmann & Paul-Henri Lambert, Birkhäuser Publishers, Basel 2005, pp. 99-118.

Epidemiology and Threat Assessment Surveillance

  1. Tovanabutra S, Brodine SK, Mascola JR, Sankale JL, Sanders-Buell E, Kim B, Birx DL, McCutchan FE. Characterization of complete HIV type 1 genomes from non-B subtype infections in U.S. military personnel. AIDS Res Hum Retroviruses. 2005 May;21(5):424-9.
  2. Montano SM, Sanchez JL, Laguna-Torres A, Cuchi P, Avila MM, Weissenbacher M, Serra M, Vinoles J, Russi JC, Aguayo N, Galeano AH, Gianella A, Andrade R, Arredondo A, Ramirez E, Acosta ME, Alava A, Montoya O, Guevara A, Manrique H, Sanchez JL, Lama JR, de la Hoz F, Sanchez GI, Ayala C, Pacheco ME, Carrion G, Chauca G, Perez JJ, Negrete M, Russell KL, Bautista CT, Olson JG, Watts DM, Birx DL, Carr JK; for the South American HIV Molecular Surveillance Working Group. Prevalences, Genotypes, and Risk Factors for HIV Transmission in South America. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):57-64.
  3. Meloni ST, Kim B, Sankale JL, Hamel DJ, Tovanabutra S, Mboup S, McCutchan FE, Kanki PJ. Distinct human immunodeficiency virus type 1 subtype A virus circulating in West Africa: sub-subtype A3. J Virol. 2004 Nov;78(22):12438-45.
  4. Carr JK, Nadai Y, Eyzaguirre L, Saad MD, Khakimov MM, Yakubov SK, Birx DL, Graham RR, Wolfe ND, Earhart KC, Sanchez JL. Outbreak of a West African recombinant of HIV-1 in Tashkent, Uzbekistan. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):570-5.
  5. Rios M, Fernandez J, Jaramillo P, Paredes V, Sanchez JL, Laguna-Torres VA, Carr JK, Ramirez E. Molecular Epidemiology of HIV Type 1 in Chile: Differential Geographic and Transmission Route Distribution of B and F Subtypes. AIDS Res Hum Retroviruses. 2005 Oct;21(10):835-40.
  6. Saad MD, Al-Jaufy A, Grahan RR, Nadai Y, Earhart KC, Sanchez JL, Carr JK. HIV type 1 strains common in Europe, Africa, and Asia cocirculate in Yemen. AIDS Res Hum Retroviruses. 2005 Jul;21(7):644-8.
  7. Wolfe ND, Prosser TA, Carr JK, Tamoufe U, Mpoudi-Ngole E, Torimiro JN, LeBreton M, McCutchan FE, Birx DL, Burke DS. Exposure to nonhuman primates in rural Cameroon. Emerg Infect Dis. 2004 Dec;10(12):2094-9.
  8. Kijak GH, McCutchan FE. HIV Diversity, Molecular Epidemiology, and the Role of Recombination. Curr Infect Dis Rep. 2005 Nov;7(6):480-8.
  9. Singer DE, Kiwanuka N, Serwadda D, Nalugoda F, Hird L, Bulken-Hoover J, Kigozi G, Malia JA, Calero EK, Sateren W, Robb ML, Wabwire-Mangen F, Wawer M, Gray RH, Sewankambo N, Birx DL, Michael NL. Use of stored serum from Uganda for development and evaluation of a human immunodeficiency virus type 1 testing algorithm involving multiple rapid immunoassays. J Clin Microbiol. 2005 Oct;43(10):5312-5.
  10. Beyrer C, Sripaipan T, Tovanabutra S, Jittiwutikarn J, Suriyanon V, Vongchak T, Srirak N, Kawichai S, Razak MH, Celentano DD. High HIV, hepatitis C and sexual risks among drug-using men who have sex with men in northern Thailand. AIDS. 2005 Sep 23;19(14):1535-40.
  11. Srirak N, Kawichai S, Vongchak T, Razak MH, Jittiwuttikarn J, Tovanabutra S, Rungruengthanakit K, Keawvichit R, Beyrer C, Wiboonatakul K, Sripaipan T, Suriyanon V, Celentano DD. HIV infection among female drug users in Northern Thailand. Drug Alcohol Depend. 2005 May 9;78(2):141-5. Epub 2004 Dec 8.
  12. Beyrer C, Razak MH, Jittiwutikarn J, Suriyanon V, Vongchak T, Srirak N, Kawichai S, Tovanabutra S, Rungruengthanakit K, Sawanpanyalert P, Sripaipan T, Celentano DD. Methamphetamine users in northern Thailand: changing demographics and risks for HIV and STD among treatment-seeking substance abusers. Int J STD AIDS. 2004 Oct;15(10):697-704.

Clinical Studies

  1. Spooner K, Barthel RV, Robertson J, Merritt T, Bradley W, Taylor-Means S, Crum N, Armstrong A, Agan B. Azithromcyin might not protect against Treponema pallidum infection or reactivation in HIV Type 1-infected patients. Clin Infect Dis. 2005 Aug 1;41(3):419-20.
  2. Guerrero AF, Straight TM, Eastone J, Spooner K. Gastric syphilis in an HIV-infected patient. AIDS Patient Care STDS. 2005 May;19(5):281-5.
  3. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, Blazes DL, Agan BK, Armstrong A, Fraser S, Crum NF. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer. 2005 Oct 1;104(7):1505-11.
  4. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, Blazes DL, Agan BK, Armstrong A, Fraser S, Crum NF. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer. 2005 Oct 1; 104(7):1505-11.
  5. Costello C, Nelson KE, Jamieson DJ, Spacek L, Sennun S, Tovanabutra S, Rungruengthanakit K, Suriyanon V, Duerr A. Predictors of low CD4 count in resource-limited settings: based on an antiretroviral-naive heterosexual thai population. J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):242-8.
  6. Costello C, Nelson KE, Suriyanon V, Sennun S, Tovanabutra S, Heilig CM, Shiboski S, Jamieson DJ, Robison V, Rungruenthanakit K, Duerr A. HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. Int J Epidemiol. 2005 Jun;34(3):577-84. Epub 2005 Feb 28.

Miscellaneous

  1. Dow GS, Caridha D, Goldberg M, Wolf L, Koenig ML, Yourick DL and Wang Z. 2005. Transcriptional profiling of mefloquine-induced disruption of calcium homeostasis in neurons in vitro. Genomics. 86 (5):539-550.

Oral and Poster Presentations / Published Abstracts:

Infectious Disease Society of America Meeting, San Francisco, California, October 6-9, 2005.

  1. Furtek K, Crum NF, Powell T, Bavaro M, Hale B, Truett A, Wallace MR. Antiretroviral Regimen Changes Among HIV-infected Patients in a Large Military Cohort.
  2. Spooner K, Bradley W, Barthel RV, Merritt T, Taylor-Means S, Ganesan A, Crum N, Armstrong A, Agan B. Evaluation of Syphilis Incidence and Prevalence in a U.S. Military HIV-1 Infected Patient Cohort.
  3. Crum NF, Bavaro M, Hale B, Truett A, Wallace M. Predictors for Successful Treatment Interruption Among HIV-Infected Patients.
  4. Crum NF, Furtek K, Bavaro M, Hale B, Truett A, Wallace M. Association of Highly Active Antiretroviral Therapy and Hypertension Among HIV-Infected Patients.

AIDS Vaccine 2005 Montréal, Québec, Canada - September 6 -9, 2005

  1. Deborah L. Birx, Co-chiar of the plenary session titled Clinical Trials and a roundtable on HIV-1 Vaccine Development: Perspective from the Developing World: Opportunities and Challenges, both taking place.
  2. Victoria R. Polonis Co-chair of the symposium, "B cell and antibody responses to HIV."
  3. Francine E. McCutchan, Epidemiology of HIV in Preparation for Phase III Vaccine Trials, Clinical Trials Plenary
  4. Victoria Polonis, Assessment of cross - clade neutralization Within a Panel of 60 full- length sequenced pure clade or CRF HIV-1 isolates.
  5. Dr. Fredrick Sawe, presented, "Integration of HIV Vaccine Research with Comprehensive HIV Prevention, Care and Treatment," at the roundtable on HIV-1 Vaccine Development.
  6. Stephen Mawa, Makerere University-Walter Reed Project, Kampala, Uganda, Uganda Challenges and lessons learnt from HIV Vaccine trials recruitment in Uganda
  7. Supachai Rerks-Ngam, Prime-Boost HIV Vaccine Trial Phase III, Thailand An Update of Progress in the Thai HIV Prime Boost Vaccine Trial: vCP1521 (ALVAC-HIV) + gp120 B/E (AIDSVAX B/E)

Posters:

  1. Aldrithol-2 Inactivated Preparations of HIV-1 Subtypes A, B and D Viruses as Reagents to Monitor T cell responses in HIV-infected subjects and in vaccine recipients
    Authors: Alleluiah Rutebemberwa, Julian Bess Jr., Bruce Brown, Miguel Arroyo, Michael Eller, Victoria Polonis, Mary Marovich, Francine McCutchan, Jeffrey Currier, Deborah Birx, Merlin Robb, Jeffrey Lifson and Josephine Cox.
  2. Social Impact of Participation in a Phase III HIV Vaccine Trial in Thailand
    Authors: Patricia A Morgan, Nakorn Premsri, Tuanjai Debyasuvarn, Punnee Pitisuttithum, Valai Bussaratid , Michael W. Benenson, Jerome H. Kim
  3. Rationales for Not Enrolment into A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP 1521) Priming With VaxGen gp120B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults
    Authors: Punnee Pitisuttithum, Sopon Wichianprapai, Singchai Prodsathaporn, Prasit, Chittiwatanapong, Ramase Amphaipis, Kitchai Patarakulpong, Anchana Palasudhi, Somchai Supawatin, Sanon Sungpapan, Supachai Rerks-Ngarm, Michael Benenso

3rd Conference on HIV Pathogenesis and Treatment (Rio de Janeiro, Brazil 2005)

  1. McCutchan FE. Plenary Lecture "HIV Diversity and Recombination"
  2. Malaza A., Grobler J., Maboko L., Hoelscher M., McCutchan F., Williamson C. HIV viral dynamics in individuals from Tanzania infected with single or multiple HIV subtypes. Abstract no. MoPe14.2B07.
  3. Kijak G., Tovanabutra S., Watanaveeradej V., Sanders-Buell E., Arroyo M., Moqueet N., De Souza M., Khamboonruang C., Amnajsirisuk S., Robb M., Birx D., McCutchan F. High-throughput HIV-1 genotyping in the era of recombination: a second-generation multi-region hybridization assay for Southeast Asia. Abstract no. MoOa0403.
  4. Kijak G., Tovanabutra S., Sanders-Buell E., Arroyo M., Currier J., Wegner S., Michael N., Robb M., Birx D., McCutchan F. Hidden potential for novel antiretroviral-drug resistance pathways in non-subtype B HIV-1 Abstract no. TuPe14.12B04.
  5. de Almeida S., Durelle J., Lazzaretto D., Beck J., Smith D., McCutchan A., Letendre S., Grant I., Ellis R. Cerebrospinal Fluid HIV RNA levels in patients with neurosyphilis. Abstract no. TuPe1.2C09.
  6. Miller L., Liu H., McCutchan J.A., Keiser P., Kemper C., Witt M., Leedom J., Forthal D., Richman D., Seefried E., Rigby A., Hermes A., Haubrich R. Adherence to Antiretroviral Therapy and Emergence of Resistant HIV: A Longitudinal Repeated Measures Analysis. Abstract no. WePe12.7C31.
  7. Foglia G., Langat L., Langat W., Kibaya R., Kimutai R., Kiptoo I., Sateren W., Bautista C., Renzullo P., Darden J., Wasunna M., Michael N., Robb M., Birx D. Community based study of HIV-1 infection among plantation workers in Kericho, Kenya in preparation for HIV-1 vaccine trials. Abstract no. WePp0201. 0503-51-RETV
  8. Foglia G., Kibaya R., Darden J., Sateren W., Langat L., Langat W., Kiptoo I., Bautista C., Wasunna M., Michael N., Birx D. Immunological and hematological reference range determinations for HIV-1 negative rural plantation workers in Kericho, Kenya in preparation for HIV-1 vaccine trials. Abstract no. WePe13.13P01.
  9. Foglia G., Langat L., Sateren W., Langat W., Kiptoo I., Kibaya R., Kimutai R., Bautista C., Renzullo P., Birx D. Retention at the one year follow-up among volunteers in the community-based study of HIV infection among plantation workers in Kericho, Kenya. Abstract no. WePe13.13P02.
  10. Carr J.K., Saad M., Nadai Y., Tishkova F., Eyzaguirre L., Strathdee S.A., Stachowiak J., Beyrer C., Earhart K., Birx D., Sanchez J.L. Outbreak of a West African HIV-1 recombinant, CRF02_AG, in Central Asia Abstract no. MoOa0407.
  11. Crum NF, Powell T, Bavaro M, Hale B, Truett A, Wallace MR and the Tri-Service AIDS Clinical Consortium. The Changing Role of the HIV Provider: Increasing Care of Non HIV-Related Conditions. Abstract MoPe11.6C10.
  12. Crum NF, Powell T, Olson P, Furtek F, Brandt C, Pope B, Bavaro M, Truett A, Hale B, Wallace MR and the Tri-Service AIDS Clinical Consortium. Association Between Cholesterol Levels and Erectile Dysfunction Among HIV-Infected Men. Abstract TuPe2.5C01.
  13. Ganesan A, Crum N, Moise M, Furtek K, Wallace M, Wegner S, Williams C, Qin J, McKaig R, Tasker S. Improvements in Serum HDL with the Use of Atazanavir Based Regimens - Observations for Two Clinic Practices. Abstract TuPe2.2B10.
  14. Furtek K, Crum NF, Powell T, Hale B, Bavaro M, Truett A, Wallace MR, and the Tri-Service AIDS Clinical Consortium. Immunologic and Virologic Responses With Combination Didanosine/Tenofovir Compared to Other Nucleoside Regimens. Abstract WePe3.2C05.

Seventh International Congress on AIDS in Asia and the Pacific, Kobe, Japan, July 1-5, 2005

  1. Kijak G., Tovanabutra S., Watanaveeradej V., Moqueet N., De Souza M., Khamboonruang C., Amnajsirisuk S., Birx D., Robb M., McCutchan F. Novel Genotyping Tool for Complex HIV-1 Epidemics in Southeast Asia. Abstract: MoA02-02

Cambridge Health Institute's Nucleic Acid-Based technologies June 27 - 28, 2005 Baltimore, Md.

  1. Asha Rathi, John Cooley, Juan Salazar, Katherine Spooner, Justin Radolf, Nelson Michael, Linda Jagodzinski. Real Time PCR Detection of treponema pallidum: A time course correlation with a antibody response.

Keystone Conference: Banff, Alberta Canada April 9- 15, 2005. HIV Vaccines: Current Challenges and Future Prospects.

Abstracts :

  1. Arryo MA, Hoelscher M, Satern W, SchoenG, Samky E, MabokoL, Hoffmann O, Sanders- Buell E, Gustavo K, Robb MR, Birx DL, McCutchanFE. Cohort development (CODE) study suggests that HIV-1 diversity and prevalence differ between urban and rural areas in Mbeya region, Tanzania.
  2. Kristina K Peachman, Taher Sathaliyawala, Victoria R Polonis, Deborh L Birx, Carl R. Alving, Venigalla B Rao, Mangala Rao. A tanscutaneous immunization strategy for DNA / protein vaccination against hiv-1 p24.
  3. B Lloyd, R OConnell, N Michael, R Aviles, J Cooley, L Jadogzinski. Prevalence of Genotypic Resistance Mutations Among Antiretroviral Therapy-Naïve HIV-1-Infected Patients in Honduras
  4. Speaker Abstract: S. Piyasirisilp, M Arroyo, S Tovanabutra, G Kijak, E. Sanders- Bueell, F McCutchan* (presenter) Screening for HIV-1 Dual Infection in Population Exposed to Multiple Subtypes.

12th Conference on Retroviruses and Opportunistic Infections Boston, MA, February 22-25, 2005.

  1. Crum N, Wallace M, Powell T, Olson P, Amling C, Pope B, Brandt C, Bavaro M, Hale B, and the Tri-Service AIDS Clinical Consortium. Prevalence and Correlates of Erectile Dysfunction and Hypogonadism among HIV-Infected Men: A Prospective Study. Abstract no.875.